PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of eidEmerging Infectious Diseases
 
Emerg Infect Dis. 2001 Sep-Oct; 7(5): 820–827.
PMCID: PMC2631870

Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery.

Abstract

Routine us of vancomycin for perioperative prophylaxis is discouraged, principally to minimize microbial resistance to it. However, outcomes and costs of this recommendation have not been assessed. We used decision-analytic models to compare clinical results and cost-effectiveness of no prophylaxis, cefazolin, and vancomycin, in coronary artery bypass graft surgery. In the base case, vancomycin resulted in 7% fewer surgical site infections and 1% lower all-cause mortality and saved $117 per procedure, compared with cefazolin. Cefazolin, in turn, resulted in substantially fewer infections and deaths and lower costs than no prophylaxis. We conclude that perioperative antibiotic prophylaxis with vancomycin is usually more effective and less expensive than cefazolin. Data on vancomycin's impact on resistance are needed to quantify the trade-off between individual patients' improved clinical outcomes and lower costs and the future long-term consequences to society.

Full Text

The Full Text of this article is available as a PDF (76K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med. 1999 Feb 18;340(7):556–557. [PubMed]
  • Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999 Feb 18;340(7):493–501. [PubMed]
  • Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis. 1998 May;26(5):1200–1203. [PubMed]
  • Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol. 1998 Aug;19(8):539–545. [PubMed]
  • Woods RK, Dellinger EP. Current guidelines for antibiotic prophylaxis of surgical wounds. Am Fam Physician. 1998 Jun;57(11):2731–2740. [PubMed]
  • Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, McGowan JE, Jr, Sweet RL, Wenzel RP. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis. 1994 Mar;18(3):422–427. [PubMed]
  • Page CP, Bohnen JM, Fletcher JR, McManus AT, Solomkin JS, Wittmann DH. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg. 1993 Jan;128(1):79–88. [PubMed]
  • Kaiser AB. Antimicrobial prophylaxis in surgery. N Engl J Med. 1986 Oct 30;315(18):1129–1138. [PubMed]
  • Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. French Study Group on Antimicrobial Prophylaxis in Surgery, French Society of Anesthesia and Intensive Care. Infect Control Hosp Epidemiol. 1994 Jul;15(7):463–471. [PubMed]
  • L'Ecuyer PB, Murphy D, Little JR, Fraser VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis. 1996 Mar;22(3):424–429. [PubMed]
  • Mossad SB, Serkey JM, Longworth DL, Cosgrove DM, 3rd, Gordon SM. Coagulase-negative staphylococcal sternal wound infections after open heart operations. Ann Thorac Surg. 1997 Feb;63(2):395–401. [PubMed]
  • Kim C, Kwok YS, Saha S, Redberg RF. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. Am Heart J. 1999 Jun;137(6):1019–1027. [PubMed]
  • Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol. 1998 Jun 15;81(12):1393–1399. [PubMed]
  • Platt R, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS, Burke JF, Wikler MA, Marino SK, Holbrook KF, et al. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med. 1990 Jan 18;322(3):153–160. [PubMed]
  • Kaiser AB, Clayson KR, Mulherin JL, Jr, Roach AC, Allen TR, Edwards WH, Dale WA. Antibiotic prophylaxis in vascular surgery. Ann Surg. 1978 Sep;188(3):283–289. [PubMed]
  • Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS, Burke JF, Wikler MA, Marino SK, et al. Prophylaxis against wound infection following herniorrhaphy or breast surgery. J Infect Dis. 1992 Sep;166(3):556–560. [PubMed]
  • Bold RJ, Mansfield PF, Berger DH, Pollock RE, Singletary SE, Ames FC, Balch CM, Hohn DC, Ross MI. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg. 1998 Sep;176(3):239–243. [PubMed]
  • Bencini PL, Galimberti M, Signorini M, Crosti C. Antibiotic prophylaxis of wound infections in skin surgery. Arch Dermatol. 1991 Sep;127(9):1357–1360. [PubMed]
  • Garrelts JC, Horst WD, Silkey B, Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy. 1994 Jul-Aug;14(4):438–445. [PubMed]
  • Maki DG, Bohn MJ, Stolz SM, Kroncke GM, Acher CW, Myerowitz PD. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1423–1434. [PubMed]
  • Ghali WA, Ash AS, Hall RE, Moskowitz MA. Statewide quality improvement initiatives and mortality after cardiac surgery. JAMA. 1997 Feb 5;277(5):379–382. [PubMed]
  • VandenBergh MF, Kluytmans JA, van Hout BA, Maat AP, Seerden RJ, McDonnel J, Verbrugh HA. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol. 1996 Dec;17(12):786–792. [PubMed]
  • Zoutman D, McDonald S, Vethanayagan D. Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center. Infect Control Hosp Epidemiol. 1998 Apr;19(4):254–259. [PubMed]
  • Hall RE, Ash AS, Ghali WA, Moskowitz MA. Hospital cost of complications associated with coronary artery bypass graft surgery. Am J Cardiol. 1997 Jun 15;79(12):1680–1682. [PubMed]
  • Penketh AR, Wansbrough-Jones MH, Wright E, Imrie F, Pepper JR, Parker DJ. Antibiotic prophylaxis for coronary artery bypass graft surgery. Lancet. 1985 Jun 29;1(8444):1500–1500. [PubMed]
  • Fong IW, Baker CB, McKee DC. The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-blind randomized trial. J Thorac Cardiovasc Surg. 1979 Dec;78(6):908–913. [PubMed]
  • Suter F, Avai A, Fusco U, Gerundini M, Caprioli S, Maggiolo F. Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):793–796. [PubMed]
  • Vuorisalo S, Pokela R, Syrjälä H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol. 1998 Apr;19(4):234–239. [PubMed]
  • Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993 Apr-Jun;13(2):89–102. [PubMed]
  • Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1997 Jan 9;336(2):92–99. [PubMed]
  • Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med. 1998 Jan;46(1):29–38. [PubMed]
  • Lawrence L, Hall MJ. 1997 summary: National Hospital Discharge Survey. Adv Data. 1999 Aug 18;(308):1–16. [PubMed]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention